Products
| Product | Strength | Pack Size |
|---|---|---|
| Azacitidine Powder for Suspension for Injection (Xpreza) | 100mg | 1 vial / box |
| Bendamustine Hydrochloride Powder for Concentrate for Solution for Infusion (Bemunat) | 100mg | 1 vial / box |
| Imatinib Tablets | 100mg | 60 tablets / box 120 tablets / box |
| Imatinib Tablets | 400mg | 30 tablets / box 90 tablets / box |
* The above product list shows our products which are approved by Hong Kong Department of Health only. It does not mean that all products are already placed in the market. For any product or business enquiries please contact us at ichk@ichk.org or (852) 2891 0581 for further details.
Leukemia
Leukemia
Leukemia refers to cancer of the early blood forming cells, most commonly in white blood cells. Depending on the rate of growth and the origin, leukemia can be divided into various types.
Targeted therapy
Imatinib is indicated for the treatment of different phases of chronic myeloid leukemia or newly diagnosed acute lymphoblastic leukemia and the treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukemia. Studies have supported its efficacy and safety in treatment of leukemia. Its estimated overall survival rate at 10 years is 83.3% in patients of the imatinib group and approximately half of the patients has been randomly assigned to imatinib. In terms of safety, serious side effects are not common and they mostly occur during the first year of treatment.
Chemotherapy
Azacitidine is an anti-neoplastic agent indicated for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, in adults who are not eligible for hematopoietic stem cell transplantation. It exerts its therapeutic action by promoting the restoration of normal gene differentiation and proliferation or exerting direct toxicity to abnormal hematopoietic cells in the bone marrow. Studies have supported azacitidine’s efficacy for patients with acute myeloid leukemia and low bone marrow blast count. Azacitidine has superior median survival and lower induction of mortality (11%) in the first few months of treatment. Azacitidine is generally well tolerated in older patients. The most common grade 3 or 4 adverse event is myelosuppression. However, the toxicity is transient and not cumulative. It is more common during early treatment cycles and typically decreases over time.
Bendamustine is indicated for chronic lymphocytic leukemia and refractory non-Hodgkin lymphoma. It causes cell death by interfering with single and double strand DNA cross linking. Bendamustine has demonstrated efficacy by showing an overall response rate of 88.2% with complete remission. After 24 months of follow-up, progression free survival is 52% and the overall survival is 69.7%. Among adverse events associated with withdrawal, infections are the most common e.g. neutropenia and thrombocytopenia. Special attention should be paid to the infectious complications, especially immune disorders.
Leukemia refers to cancer of the early blood forming cells, most commonly in white blood cells. Depending on the rate of growth and the origin, leukemia can be divided into various types.
Targeted therapy
Imatinib is indicated for the treatment of different phases of chronic myeloid leukemia or newly diagnosed acute lymphoblastic leukemia and the treatment of advanced hypereosinophilic syndrome and chronic eosinophilic leukemia. Studies have supported its efficacy and safety in treatment of leukemia. Its estimated overall survival rate at 10 years is 83.3% in patients of the imatinib group and approximately half of the patients has been randomly assigned to imatinib. In terms of safety, serious side effects are not common and they mostly occur during the first year of treatment.
Chemotherapy
Azacitidine is an anti-neoplastic agent indicated for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia, in adults who are not eligible for hematopoietic stem cell transplantation. It exerts its therapeutic action by promoting the restoration of normal gene differentiation and proliferation or exerting direct toxicity to abnormal hematopoietic cells in the bone marrow. Studies have supported azacitidine’s efficacy for patients with acute myeloid leukemia and low bone marrow blast count. Azacitidine has superior median survival and lower induction of mortality (11%) in the first few months of treatment. Azacitidine is generally well tolerated in older patients. The most common grade 3 or 4 adverse event is myelosuppression. However, the toxicity is transient and not cumulative. It is more common during early treatment cycles and typically decreases over time.
Bendamustine is indicated for chronic lymphocytic leukemia and refractory non-Hodgkin lymphoma. It causes cell death by interfering with single and double strand DNA cross linking. Bendamustine has demonstrated efficacy by showing an overall response rate of 88.2% with complete remission. After 24 months of follow-up, progression free survival is 52% and the overall survival is 69.7%. Among adverse events associated with withdrawal, infections are the most common e.g. neutropenia and thrombocytopenia. Special attention should be paid to the infectious complications, especially immune disorders.